EN DE
Watch ACCRELIST LTD for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ACCRELIST LTD (QZG) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of ACCRELIST LTD stock S$0.03, price S$0.06, that is 49.9% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG

AL ACCRELIST LTD logo Thin data Nov 10, 2026

ACCRELIST LTD

QZG · SG

Far too expensive (fair value 50% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Generates free cash flow 
Revenue last quarter +28% vs. a year ago. 
Quality 53/100 
Changed on Nov 5: S$0.0331 → S$0.0254 
Fair value 0.0290 SGD · Strongly overvalued 
Weak Growth (revenue 5y −36.5 %/yr in SGD) 
Loss-making · -7.3% net margin (TTM) 
Trails peers (3/11) 
Narrow moat 9/100 · thin data
Thin data 
Watch ACCRELIST LTD for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.2050 SGD 0.0290 SGD Fair Value 0.0290 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 0.0290 SGD – 0.2050 SGD · the 0.0580 SGD price screens above the 0.0290 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ACCRELIST in your weekly email

Every Wednesday you see whether ACCRELIST is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Accrelist Ltd., an investment holding company, engages in the medical aesthetics business in Singapore, Malaysia, and Indonesia. It operates through three segments: Mechanical Business Unit (MBU), Aesthetic Medical Services (AMS), and Others segment.

Show moreShow less

The MBU segment offers mould design and fabrication services for consumer electronics, household appliances, automotive, and computer peripherals, as well as precision plastic injection moulding services for customers' finished products.

Its AMS segment offers aesthetic services and solutions, including cosmetic dermatology and skin laser services.

The company is also involved in the operation of aesthetic medical clinics; retail sale of pharmaceutical and medical goods; and development and distribution of original design manufacturer (ODM) clinical skincare products and other non-ODM products.

The company was formerly known as WE Holdings Ltd. and changed its name to Accrelist Ltd. in November 2016. Accrelist Ltd. was founded in 1986 and is headquartered in Singapore.

Stock analysis

ACCRELIST LTD (QZG) currently trades at 0.0580 SGD, while our model-based Fair Value estimate is 0.0290 SGD, 50% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.0200 SGD per share, and 1 of the 6 models we run sit above the 0.0580 SGD price.

Bear case: the DCF Models group reads lowest at 0.0150 SGD, and 5 of the 6 models stay below the price. Data coverage for this calculation is low.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

ACCRELIST LTD reported revenue of 15.6M SGD in FY2026 versus 241M SGD in FY2022, a compound −49.5%/yr. Reported net income was −264K SGD in FY2026.

Key figures

Market cap 18.6M SGD (≈ $14.5M) Micro · P/S ratio 1.74 · Net margin −1.7% · Return on equity −18.4% · Return on assets (EBIT) −13.6% (5-year average) · Operating margin −32.3% · Revenue (TTM) 15.6M SGD · Revenue growth (YoY) +27.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 72% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −50%, QZG screens richer than that median.

Fair Value models

Bear 0.0290 SGD Fair Value 0.0290 SGD Bull 0.0290 SGD
Price 0.0580 SGD · Downside -49.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.0100 SGD 0.0200 SGD 0.0200 SGD 82
Growth DCF 0.0100 SGD 0.0200 SGD 0.0200 SGD 80
Owner Earnings 0.0600 SGD 0.0900 SGD 0.1400 SGD 76
All 6 models by family
DCF Models
FCF DCF 0.0100 SGD 0.0200 SGD 0.0200 SGD 82
Owner Earnings 0.0600 SGD 0.0900 SGD 0.1400 SGD 76
5Y Revenue Exit 0.0100 SGD 0.0100 SGD 0.0100 SGD 74
10Y Revenue Exit 0.0100 SGD 0.0100 SGD 0.0100 SGD 68
Asset-Based
NCAV (Graham) 0.0100 SGD 0.0200 SGD 0.0300 SGD 52
Growth DCF
Growth DCF 0.0100 SGD 0.0200 SGD 0.0200 SGD 80

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 27
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 60
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 47
Distance to the 52-week high, does not count
New shares 70
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.6% (2021) → −17.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+41.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +38.7% a year for the price.

QZG screens overvalued: fair value 50% below the price. Compare with HCA Healthcare, Inc →

Compare ACCRELIST LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −50.0% · Bottom 25%
Profitability
Return on assets −1.2% · Bottom 25%
Net margin (12 months) −7.3% · Bottom 25%
Operating margin (12 months) −32.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 27.8% · Top 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 2.06× · Pricier than median
P/S (12 months) 1.19× · Cheaper than median
Price / free cash flow (fiscal year) 144.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)100 · sector 33
PAST (return on equity)0 · sector 32
HEALTH (low debt)100 · sector 90
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs QZG
DaVita Inc DVA $174.56 $218.90 +25% vs QZG
Aier Eye Hospital Group 300015 ¥8.99 ¥10.88 +21% vs QZG
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs QZG
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs QZG
The Ensign Group ENSG $188.41 $140.09 −26% vs QZG
Encompass Health Corporation EHC $140.99 $94.81 −33% vs QZG
Fresenius SE FRE €53.86 €34.77 −35% vs QZG
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,771 ₹5,234 −40% vs QZG
Dr. Sulaiman Al Habib Medical Services Group 4013 211.40 SAR 109.45 SAR −48% vs QZG

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ACCRELIST LTD: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ACCRELIST LTD Fair Value". https://www.fairvalue-calculator.com/stock/QZG

Frequently asked questions

Is ACCRELIST LTD (QZG) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of 0.0290 SGD versus a price of 0.0580 SGD, about 50% lower (overvalued).
What is the fair value of QZG?
Our model-based fair value for ACCRELIST LTD is 0.0290 SGD (as of Nov 10, 2026), built from audited fundamentals. The current price: 0.0580 SGD.
What is the quality score of QZG?
ACCRELIST LTD has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ACCRELIST LTD (QZG)?
Our model-based price target is the fair value of 0.0290 SGD (as of Nov 10, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the ACCRELIST LTD stock forecast for 2026?
Our models put fair value at 0.0290 SGD, about 50% lower versus a price of 0.0580 SGD (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of ACCRELIST LTD (QZG)?
ACCRELIST LTD reported trailing-twelve-month revenue of about 15.6M SGD (latest available figure, as of Nov 10, 2026).
What growth is priced into ACCRELIST LTD (QZG)?
For today's price to be fair in a discounted-cash-flow model, ACCRELIST LTD would have to grow free cash flow by 41.6 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 36.5 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of QZG use?
Our models discount ACCRELIST LTD at 8.3 %: a base by market capitalisation (nano), damped by beta 0.46, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ACCRELIST LTD that is +41.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has ACCRELIST LTD (QZG) delivered so far?
Over the past 5 years revenue at ACCRELIST LTD shrank 36.5 % a year. The price currently implies free-cash-flow growth of +41.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ACCRELIST LTD (QZG) growing?
The median revenue growth in the sector is +12.0 % a year. That is the yardstick for the growth priced into ACCRELIST LTD (+41.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ACCRELIST LTD (QZG)?
The free-cash-flow yield on the price is 0.69 %: that much free cash flow ACCRELIST LTD produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ACCRELIST LTD (QZG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACCRELIST LTD it is 0.0290 SGD per share (as of Nov 10, 2026), against a price of 0.0580 SGD. It is the blended result of 6 valuation models in 3 families (DCF Models, Asset-Based, Growth DCF).
Is ACCRELIST LTD stock overvalued or undervalued in 2026?
As of Nov 10, 2026, QZG trades above its calculated fair value: price 0.0580 SGD, fair value 0.0290 SGD, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QZG?
No. The price is what the market pays today (0.0580 SGD); the fair value is what the company's own numbers justify (0.0290 SGD). For ACCRELIST LTD the two are 0.0290 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is ACCRELIST LTD worth?
The market values ACCRELIST LTD at about 18.6M SGD (market capitalisation, as of Nov 10, 2026). Per share that is 0.0580 SGD; our models calculate a fair value of 0.0290 SGD per share.
How solid is the balance sheet of ACCRELIST LTD (QZG)?
Balance-sheet figures for ACCRELIST LTD (as of Nov 10, 2026): return on equity −18.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is QZG from its 52-week high?
ACCRELIST LTD trades at 0.0580 SGD, about 72% below its 52-week high of 0.2050 SGD and 49% above the low of 0.0390 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0290 SGD is for.
Which stocks are comparable to ACCRELIST LTD?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ACCRELIST LTD stock attractive at the current price?
The data as of Nov 10, 2026: price 0.0580 SGD, calculated fair value 0.0290 SGD (−50%), Quality Score 53/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QZG calculated?
We run ACCRELIST LTD through 6 models from 3 families: DCF Models, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 0.0290 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. ACCRELIST LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ACCRELIST LTD (QZG)?
The closing price on Nov 16, 2026 was 0.0580 SGD. Our model-based fair value is 0.0290 SGD, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ACCRELIST LTD right now?
The price sits above even our optimistic bull case (0.0290 SGD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of ACCRELIST LTD

How large is the market capitalisation of ACCRELIST LTD (QZG)?
The market capitalisation of ACCRELIST LTD is 18.6M SGD (≈ $14.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ACCRELIST LTD (QZG)?
The price-to-sales ratio of ACCRELIST LTD is 1.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ACCRELIST LTD (QZG)?
The net margin of ACCRELIST LTD is −1.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ACCRELIST LTD (QZG)?
The return on equity (ROE) of ACCRELIST LTD is −18.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ACCRELIST LTD (QZG)?
On an EBIT basis the return on assets of ACCRELIST LTD is −13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ACCRELIST LTD (QZG)?
The operating margin of ACCRELIST LTD is −32.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ACCRELIST LTD (QZG)?
Revenue at ACCRELIST LTD is growing 27.8% versus a year earlier (3y avg −24.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ACCRELIST LTD (QZG)?
Earnings per share at ACCRELIST LTD are growing 637% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ACCRELIST LTD (QZG) carry?
The net debt of ACCRELIST LTD is 3.6M SGD (fiscal year 2022, ≈ 27.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ACCRELIST LTD in the live analysis

One click puts ACCRELIST LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.